Maria Fardis ends a two-year CEO hiatus; More leadership turnover on the menu at Galapagos
→ Following her resignation from Iovance, Maria Fardis pivoted to Frazier Life Sciences as a venture partner. But she’s back in the saddle at a Frazier upstart, taking over for Mark Barrett as CEO of San Diego-based IL-11 biotech Lassen Therapeutics. Fardis also chairs the board at Obsidian Therapeutics and has a board seat at CRISPR Therapeutics.
CMC-related delays hampered potency assays for Iovance’s tumor infiltrating lymphocyte therapy lifileucel, and Fardis stepped down not even 24 hours after the BLA for lifileucel stalled out again in 2021. To this day, a permanent replacement for interim chief and general counsel Frederick Vogt hasn’t been named.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters